ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) reported Q3 EPS of ($0.16), $0.02 better than the analyst estimate of ($0.18).

For earnings history and earnings-related data on ARS Pharmaceuticals, Inc. (SPRY) click here.